{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:48:50Z","timestamp":1790513330080,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T00:00:00Z","timestamp":1389398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s12032-013-0836-9","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T10:20:07Z","timestamp":1389349207000},"source":"Crossref","is-referenced-by-count":10,"title":["Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4\/RhoA pathway in chronic myeloid leukemia cell lines"],"prefix":"10.1007","volume":"31","author":[{"given":"Bin-Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Chun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,11]]},"reference":[{"key":"836_CR1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. IRIS investigators: six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361.","journal-title":"Leukemia"},{"key":"836_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. IRIS investigators: five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"836_CR3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038\u201342.","journal-title":"N Engl J Med"},{"key":"836_CR4","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20139.","journal-title":"Blood"},{"key":"836_CR5","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/0008-5472.CAN-07-0525","volume":"67","author":"NK Noren","year":"2007","unstructured":"Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007;67:3994\u20137.","journal-title":"Cancer Res"},{"key":"836_CR6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","volume":"23","author":"FJ Giles","year":"2009","unstructured":"Giles FJ, O\u2019Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23:1698\u2013707.","journal-title":"Leukemia"},{"key":"836_CR7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jemt.10177","volume":"59","author":"M Nakamoto","year":"2002","unstructured":"Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech. 2002;59:58\u201367.","journal-title":"Microsc Res Tech"},{"key":"836_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.2009.01387.x","volume":"84","author":"M Suzuki","year":"2010","unstructured":"Suzuki M, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, et al. BCR-ABL-independent and RAS\/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol. 2010;84:229\u201338.","journal-title":"Eur J Haematol"},{"key":"836_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1634\/stemcells.21-3-315","volume":"21","author":"K Ohmine","year":"2003","unstructured":"Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, et al. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22\/SR. Stem Cells. 2003;21:315\u201321.","journal-title":"Stem Cells"},{"key":"836_CR10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","volume":"257","author":"RM Tujebajeva","year":"1989","unstructured":"Tujebajeva RM, Graifer DM, Karpova GG, Ajtkhozhina NA. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett. 1989;257:254\u20136.","journal-title":"FEBS Lett"},{"key":"836_CR11","first-page":"2031","volume":"50","author":"JY Zhou","year":"1990","unstructured":"Zhou JY, Chen DL, Shen ZS, Koeffler HP. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res. 1990;50:2031\u20135.","journal-title":"Cancer Res"},{"key":"836_CR12","first-page":"1155","volume":"23","author":"R Li","year":"2004","unstructured":"Li R, Liu XL, Du QF, Zhang S, Zhou SY. Two-dimensional polyacrylamide gel electrophoresis analysis of apoptosis in K562 cells induced by harringtonine. Ai Zheng. 2004;23:1155\u201360.","journal-title":"Ai Zheng"},{"key":"836_CR13","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/sj.onc.1206626","volume":"22","author":"T Harnois","year":"2003","unstructured":"Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N. Differential interaction and activation of Rho family GTPases by p210 bcr-abl and p190 bcr-abl. Oncogene. 2003;22:6445\u201354.","journal-title":"Oncogene"},{"key":"836_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/187152908786786241","volume":"8","author":"K Kuzelov\u00e1","year":"2008","unstructured":"Kuzelov\u00e1 K, Hrkal Z. Rho-signaling pathways in chronic myelogenous leukemia. Cardiovasc Hematol Disord Drug Targets. 2008;8:261\u20137.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"836_CR15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","volume":"94","author":"S O\u2019Brien","year":"2002","unstructured":"O\u2019Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic phase chronic myelogenous leukemia. Cancer. 2002;94:2024\u201332.","journal-title":"Cancer"},{"key":"836_CR16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-010-0991-4","volume":"89","author":"B Fang","year":"2010","unstructured":"Fang B, Li N, Song Y, Han Q, Zhao RC. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann Hematol. 2010;89:1099\u2013105.","journal-title":"Ann Hematol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0836-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-013-0836-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0836-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:29Z","timestamp":1559442149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-013-0836-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,11]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s12032-013-0836-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,11]]},"article-number":"836"}}